18 Infos zu Juerg Eckhardt

5 Aktuelle Nachrichten

Markus Hosang of Biomedinvest AG and Juerg Eckhardt of Bellevue Asset Management AG continue to serve as members of the Board of Directors, which is chaired by Oern Stuge, MD. Mr. Stuge has a long-standing management track record with healthcare companies such as Medtronic Inc. and Abbott ...

Vaximm Holding, a joint venture between Merck and a Swiss investment fund, will start testing an experimental cancer vaccine in patients

Growth Capital in Healthcare

"It's the next, the better Avastin," and will target similar types of cancers as the Roche drug, BB Biotech Ventures partner Juerg Eckhardt said in ...

2 Profile in Sozialen Netzwerken

Juerg Eckhardts berufliches Profil anzeigen LinkedIn ist das weltweit größte berufliche Netzwerk, das Fach- und Führungskräften wie Juerg Eckhardt dabei hilft, ... Es fehlt: aschaffenburg

2 Firmen-Beteiligungen

Business Connection. Senior Investment Advisor at Bellevue Group AG. Affiliated with Calypso Medical. Senior Investment Advisor at BB Biotech Ventures.

Juerg Eckhardt, M B A PAST show details and sources... Education (M B A) [Past] · Kurt Bjoerklund, M B A – Economics PAST show details and sources.

2 Meinungen & Artikel

1 post published by Steven R. Gerbsman on January 26, 2015

Juerg Eckhardt, BB Biotech-Zurich. Alfred Scheidegger, PhD- Nextech Invest Ltd-Zurich. * indicates current board member. The Bidding Process for Interested Buyers Interested and qualified parties will be expected to sign a nondisclosure agreement (attached hereto as Exhibit A) to have access to key ...

7 Webfunde aus dem Netz

View Juerg Eckhardt's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Juerg Eckhardt discover ... Es fehlt: aschaffenburg

The first product, which is supported by an attractive follow-on pipeline, is already approaching clinical trials,” says Juerg Eckhardt, investment ...

"It's the next, the better Avastin," and will target similar types of cancers as the Roche drug, said Juerg Eckhardt, a BB Biotech Ventures partner. "It's early, but it has lots of potential." Merck owns 25% of the Vaximm joint venture, Phyllis Carter, a spokeswoman for the drugmaker, said. The venture fund owns 68%, Eckhardt ...

Dr. Juerg Eckhardt of BB Biotech Ventures will join the board as part of the deal. TargeGen is developing small molecule kinase inhibitors targeted at the ...